Chiron Corporation

Biotium, Inc.

Cytyc Health Corporation

Hui Cen

Fei Mao

Wai-Yee Leung

W Michael Kavanaugh

Pauline Lee

Lewis T Williams

David T Hung

Susan M Love

Enzyme substrates and associated technology of the present invention are provided. An enzyme substrate of the invention may comprise a biologically functional fluorescent dye and an enzyme-specific substrate moiety attached in such a way that the functionality of the functional dye is diminished. An enzymatic reaction may cleave at least a portion of the substrate moiety from the enzyme substrate to provide a more functional product dye. This product dye may be nonfluorescent or weakly fluorescent, in general, and relatively fluorescent, in a particular condition, such as when bound to a partner biological molecule or an assembly of partner biological molecules. An enzyme substrate of the present invention may thus be useful in fluorescence detection, and/or in any of a variety of useful applications, such as the detection of enzymatic activity in a cell-free system or in a living cell, the screening of drugs, or the diagnosis of disease.

Enzyme substrate comprising a functional dye and associated technology and methods

This invention relates to mouse and human EGFH2, and to variants thereof and to polynucleotides encoding EGFH2. This invention also relates to therapeutic agents related to the polynucleotides and proteins.

EGFH2 genes and gene products

Antibodies to EGFH2 polypeptides

The invention is to methods for screening women for breast cancer and precancer by determining a level of an estrogen-related marker. The invention further provides methods of treating such patients identified as having one or more abnormal ductal epithelial cells and an estrogen-related marker. The invention provides methods for screening patient for hormone replacement therapy (HRT), and of monitoring such patients once they begin HRT. The invention provides methods of treating peri-, menopausal or postmenopausal women for both cancer risk reduction and menopausal symptoms (or other conditions related to lowered systemic estrogen levels). The invention also provides kits for the screening, monitoring, and treating methods described.

Identifying, monitoring, and treating women for breast precancer or cancer

A mammalian protein involved in receptor-mediated endocytosis specifically binds to phosphatidylinositol 3-kinase. More specifically it binds to the Bcr homology domain of the p85 subunit of phosphatidylinositol 3-kinase. Phathoidylinositol 3-kinase also binds to platelet derived growth factor receptor. Other receptors may also bind, including those for insulin, insulin-like growth factor-1, colony stimulating factor 1, nerve growth factor, hepatocyte growth factor, stem cell growth factor, and epidermal growth factor. Mitogenesis is the consequence of the binding and internalization of these growth factors. Inhibition of the process of receptor-mediated internalization inhibits mitogenesis.

.gamma. II adaptin

Growing community of inventors

Oakland, CA, United States of America

Hui Cen